Figure 4
From: Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
Validation and pathway analysis of mesothelioma-derived exosome cargo.
(a) To validate the relative abundance of proteins identified using GeLC-MS/MS, Western blot analysis was used to compare expression for selected proteins; glypican-1 (HSPG1/GPC1), mesothelin (MSLN), calreticulin (CALR), and other exosome components protocadherin Fat 1 (FAT1), CD81, and CD70. For Western blotting, exosomes (10 μg) were separated by 1D-SDS-PAGE, electrotransferred, and probed with markers as indicated (n = 2). (b) Relative quantitation of label-free spectral counting (SpC) are shown for selected proteins validated using Western immunoblotting (n = 3). (c) Immune system and immune disease related pathways in MM-derived exosomes, with p-values indicated. (d) Cancer cell biology related pathways in MM-derived exosomes, with p-values indicated. (e) Signal transduction related pathways in MM-derived exosomes, with p-values indicated.
